11 results about "Intestinal Disorder" patented technology

The invention belongs to the technical field of magnetic control micro-robots and intelligent control, and relates to a mudskipper-imitating magnetic control micro-robot and a control method thereof.The mudskipper-imitating magnetic control micro-robot system comprises a robot body and a control part, and the robot body is composed of two magnetic driving sub-modules and an energy storage module; the two magnetic driving sub-modules are symmetrically fixed at two ends of the energy storage module at a preset interval, and the energy storage module is used for realizing non-magnetic connection of the two magnetic driving sub-modules; the control part comprises a magnetic field generation module for forming a driving magnetic field around the robot body and a controller for adjusting the magnetic field generation module to change the magnetic field intensity and direction so as to drive the robot body to realize jumping motion; the robot designed by the invention can adapt to large deformation of intestinal peristalsis, efficiently cross mucous membrane wrinkles, adapt to unstructured characteristics of intestinal tracts, and can accurately reach a focus area to provide a path for accurate diagnosis and treatment of intestinal diseases.

This invention relates to an orally administrated nutritional supplement for the management of symptoms of irritable bowel syndrome (IBS) and related functional disorders. The composition includes:1) zinc-L-carnosine 60-100 mg per daily dose or an equivalent combination of zinc and L-carnosine providing 16?20 mg elemental Zn and 55-60 mg L-carnosine; 2) extract of Boswellia serrata resin with 25-35% total AKBA yielding 60-90 mg AKBA; 3) a probiotic blend 30-100 billion CFU that includes, at least, one strain from the genera Streptococcus, Bifidobacterium, and Lactobacillus. The active ingredients are incorporated into an acid-resistant or slow-release pharmaceutical form which limits their release in gastric pH and releases them when the pH is "greater than or equal to" 5.5, ensuring their integrity until they reach the intestine. The combination of the three above components strengthens the intestinal barrier, reduces intestinal inflammation, and restores the intestinal microbiota, providing comprehensive support to patients with IBS and related functional intestinal disorders.

This invention discloses the application of Jerusalem artichoke polysaccharide in the preparation of drugs for regulating intestinal flora, belonging to the field of intestinal flora drugs. The drugs for regulating intestinal flora use Jerusalem artichoke polysaccharide as the active ingredient. These drugs improve intestinal disorders by increasing the proliferation of beneficial intestinal bacteria and the content of short-chain fatty acids, metabolites of intestinal flora. The Jerusalem artichoke polysaccharide prepared by this invention contains uronic acid and pyranose, and is mainly composed of fructose and glucose, with an average molecular weight of 2228 Da. The preparation method of Jerusalem artichoke polysaccharide in this invention has high yield, low cost, and is suitable for industrial production.

The application provides a preparation method and application of a gastrointestinal microenvironment responsive nano-coated probiotic, so as to improve the bioavailability of the probiotic and realize the purpose of synergistically treating intestinal diseases by combining with a therapeutic drug. The gastrointestinal microenvironment responsive nano-coated probiotic is a seaweed salt which forms a coating on the surface of a single probiotic by chelating with calcium ions, and can also coat small molecule anti-inflammatory drugs to protect the probiotic from the gastric environment. When reaching the intestinal neutral environment, the coating is dissolved, and the inhibited probiotic and therapeutic drug are synchronously released. The probiotic inhibits the growth of pathogenic bacteria, maintains the intestinal flora, and maintains the balance of the intestinal flora; meanwhile, the anti-inflammatory effect of the drug is combined, so that the effect of synergistically treating intestinal diseases is achieved.

The invention discloses an intestinal disease detection device based on a tapering multimode fiber ring laser. According to the device, a tapering multimode fiber is prepared through a tapering multimode fiber preparation module by adopting a fused biconical taper method; functional modification is performed on the surface of an optical fiber taper region of the tapering multimode optical fiber through a tapering multimode optical fiber functional module, and a specific antibody of an intestinal disease marker is fixed; an intestinal disease marker detection module is integrated in an optical fiber ring laser system by utilizing a functionalized sensing probe, the laser wavelength drift distance is detected through the optical fiber ring laser system, an intestinal disease marker is detected according to the laser wavelength drift distance, and an intestinal disease detection result is obtained. The spectral line width can be effectively compressed, and the signal-to-noise ratio is improved, so that high-precision, high-sensitivity and rapid label-free detection of the intestinal disease marker is realized.

This document describes the use of the CRB1 gene in the preparation of drugs for treating systemic diseases such as eye and intestinal disorders. It also describes the use of CRB1 gene-based therapeutics in the preparation of drugs for treating systemic diseases such as eye and intestinal disorders.

Where an implanted reservoir for intestinal contents is formed from surgically modified intestine that has been cut along a mutual contact line of laterally adjacent sections of a bent portion of intestine and connected so that the resulting upper and lower halves of the intestine form an intestinal wall of the reservoir, the system for emptying such intestinal reservoir comprises an artificial flow control device implantable in the patient's body and adapted to control flow of the intestinal contents from said reservoir, the flow control device comprising at least one pump adapted to act on said intestinal wall so as to reduce the reservoir's volume, thereby emptying the reservoir. The system may further comprise an entry valve upstream of the reservoir and an exit valve downstream from the reservoir. The pump may be an electrical stimulation type pump, a hydraulically acting type pump or / and a mechanically acting type pump.

The application belongs to the technical field of biology, and discloses a reagent combination or kit for constructing an intestinal organoid and application thereof. The reagent combination or kit can obtain an intestinal organoid from donor-derived epithelial cells in a non-invasive manner, the obtained intestinal organoid can be frozen and recovered, and can be long-term expanded in vitro; the transcriptome characteristics are similar to those of real human small intestinal tissues, and a plurality of typical marker genes of small intestinal lineage cell types are highly expressed; compared with an intestinal organoid induced by pluripotent stem cells, the intestinal organoid is more characteristic of an intestinal lineage, and the intestinal function development is more mature; after the intestinal organoid is promoted to be mature, genes related to drug absorption and metabolism are also highly expressed, the intestinal organoid has similar drug absorption capacity to an immortalized intestinal cell line, but more outstandingly shows intestinal cell lineage characteristics, and is closer to a real intestinal environment in a human body, and can be used for intestinal disease drug screening; and has an intestinal barrier function.

Provided are methods for determining susceptibility of an intestinal disorder in a companion animal. These methods include measuring a first amount of a first intestinal microorganism and / or a second amount of a second intestinal microorganism in the companion animal; comparing the first amount of the first intestinal microorganism with a first reference amount of the first intestinal microorganism, and / or comparing the second amount of the second intestinal microorganism with a second reference amount of the second intestinal microorganism; and determining that the companion animal is susceptible of an intestinal disorder, when the first amount of the intestinal microorganism is higher than the first reference amount of the first intestinal microorganism, and / or when the second amount of the second intestinal microorganism is lower than the second reference amount of the second intestinal microorganism.

The invention discloses a multi-mode motion and path tracking control method and system for a magnetic control micro-robot, and relates to the technical field of magnetic control micro-robots and intelligent control systems. Aiming at the technical pain points that an existing magnetic control micro-robot is single in motion mode, low in path tracking precision in an intestinal environment and difficult to reach a focus accurately, stable triggering and flexible switching of overturning and rolling dual-mode motion are achieved by regulating and controlling the relative angle between an external magnetic field plane and the length direction of the robot; the method comprises the following steps: respectively constructing kinetic models of two motions, and realizing path tracking closed-loop control by adopting a model prediction control algorithm adaptive to an overturning characteristic and combining visual real-time feedback. The obstacle crossing ability of the robot in the complex intestinal environment is effectively improved, the path tracking precision and the control stability are remarkably improved, it can be guaranteed that the robot accurately reaches the intestinal focus, and reliable technical support is provided for accurate diagnosis and treatment of intestinal diseases.

The invention belongs to the technical field of biological medicines, and relates to specific therapeutic activity of a medicinal preparation, in particular to application of ganoderma lucidum exosome-like nanoparticles in preparation of a medicine for treating Parkinson's disease. The preparation method of the lucid ganoderma exosome-like nanoparticles comprises the following steps: crushing, soaking and grinding lucid ganoderma to break lucid ganoderma cells, so as to obtain a lucid ganoderma treatment solution; filtering the lucid ganoderma treatment liquid; wherein the filtration comprises ultrafiltration, the particle size of an ultrafiltration product is 30-400 nm, and the ultrafiltration product is the ganoderma lucidum exosome-like nano-particles. Experimental research shows that the ganoderma lucidum exosome-like nanoparticles can significantly improve intestinal disorder and intestinal mucosa injury of Parkinson rats, and improve motor and cognitive impairment.